🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for BRCA Mutation

Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer. NCT05378204NA25 sites📍 Bordeaux📍 Caen📍 Clermont-Ferrand Institut Claudius Regaud · Tests: Main study:, Sub-study: Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer NCT04090567Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Cediranib, Ceralasertib, Olaparib A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer NCT07069335Phase 11 site📍 Seoul Boryung Pharmaceutical Co., Ltd · Tests: Olaparib 150 MG Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab NCT06516289Phase 21 site📍 Shanghai Fudan University · Tests: HRS-1167, Famitinib, Camrelizumab MEASUREMENT OF CIRCULATING MUTATION BURDEN NCT06792721n/a1 site📍 Caen Centre Francois Baclesse · Tests: Mutation Burden cfMB analysis Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer NCT07371104Phase 11 site📍 Seoul Daewoong Pharmaceutical Co. LTD. · Tests: DWZ2501 (Olaparib 150mg), DWC202510 (Olaparib 150mg) A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation NCT06952803Phase 3346 sites📍 Phoenix📍 Tucson📍 La Jolla AstraZeneca · Tests: Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT) A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance NCT07321015Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Fluzoparib Monotherapy Integrated Testing Strategy for Simultaneous Detection of ESR-1 and gBRCA Mutations Via Liquid Biopsy in HR+/HER2- Metastatic Breast Cancer (mBC) Patients, NCT06762483n/a1 site📍 Milan European Institute of Oncology Population Based Germline Testing for Early Detection and Prevention of Cancer NCT07498829NA1 site📍 London Queen Mary University of London · Tests: Genetic testing for Cancer Susceptibility Genes (CSGs) (BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2, MLH1, MSH2, MSH6) a… The Cancer of the Pancreas Screening-5 CAPS5)Study NCT02000089Phase 39 sites📍 New Haven📍 Baltimore📍 Boston Johns Hopkins University · Tests: Secretin, MRI, Tumor marker gene test with CA19-9 Prediction of Germline BRCA 1/2 Genes From Healthy Ovaries NCT05769517n/a1 site📍 Rome Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Tests: Germinal BRCA Detection of Homologous Recombination Pathway Gene Mutations in Circulating Tumour DNA From BRCA-mutated Ovarian Cancer Patients Receiving First-line PARP Inhibitor Maintenance Therapy NCT06588322NA6 sites📍 Angers📍 Bordeaux📍 Limoges Institut Claudius Regaud · Tests: Blood samples will be taken on several times (36 mL of blood taken at each time): Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer: an Open, Single Arm, Multicenter Study NCT05576389Phase 21 site📍 Beijing Peking University People's Hospital · Tests: Camrelizumab+Fluzoparib A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies NCT06395519Phase 1, Phase 214 sites📍 Phoenix📍 New Haven📍 Jacksonville 858 Therapeutics, Inc. · Tests: ETX-19477 Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer NCT05485766Phase 23 sites📍 Gifu📍 Okayama📍 Tokyo Okayama University · Tests: Pembrolizumab, Paclitaxel, Carboplatin, Olaparib, Definitive Surgery Cognitive Behavioral Therapy for Fear of Cancer Recurrence in Women With BRCA1/2 Gene NCT06817694NA1 site📍 Québec CHU de Quebec-Universite Laval · Tests: Cognitive-behavioral group therapy Registry of Subjects at Risk of Pancreatic Cancer NCT04095195n/a4 sites📍 Rozzano📍 Peschiera del Garda📍 Milan Associazione Italiana per lo Studio del Pancreas · Tests: MRCP, Endoultrasonography Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations NCT00823654n/a8 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: Blood draw and questionnaires, Blood draw and questionnaires Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer NCT06783127n/a2 sites📍 Naples📍 Trento Santa Chiara Hospital · Tests: Olaparib Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation NCT03667417n/a1 site📍 Marseille Institut Paoli-Calmettes · Tests: Questionnaires BRCA Mutation Carriers' Platform a Multicenter Study NCT07253051n/a40 sites📍 Avellino📍 Aviano📍 Bari Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Tests: Registration of clinical datas in the platform MiniLap Vs Standard Laparoscopy in Prophylactic Bilateral Salpingo-oophorectomy in BRCA-Mutated Patients NCT06831747NA1 site📍 Udine Azienda Sanitaria-Universitaria Integrata di Udine · Tests: Bilateral salpingo-oophorectomy - S-LPS, Bilateral salpingo-oophorectomy - PSS The GENPET Study - An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a DNA Repair Gene Mutation. NCT05097274n/a1 site📍 London Institute of Cancer Research, United Kingdom · Tests: MRI pelvis or CT imaging under clinical management for Pr Ca, Whole body bone scan imaging, PET-CT imaging Carboplatin or Olaparib for BRcA Deficient Prostate Cancer NCT04038502Phase 218 sites📍 West Los Angeles📍 Aurora📍 Washington D.C. VA Office of Research and Development · Tests: Carboplatin, Olaparib Sweden Cancerome Analysis Network - Breast : Genomic Profiling of Breast Cancer NCT02306096n/a10 sites📍 Borås📍 Halmstad📍 Helsingborg Lund University A Prospective CohorT Study of HandX - Assisted ENdoscopic MAstectomy: Feasibility and Safety (ATHENA I Study) NCT07292246NA1 site📍 Glyfada Vasileios Kalles · Tests: Endoscopic nipple sparing mastectomy, HandX endoscopic instrument Development and Validation of an Ovarian Cancer Risk Prediction Model for Family Members of Ovarian Cancer Probands NCT07039552n/a1 site📍 Beijing Peking University Third Hospital · Tests: risk-reducing salpingo-oophorectomy (RRSO) Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors NCT06666270Phase 12 sites📍 Zhengzhou📍 Shanghai Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · Tests: SYN818 SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells NCT04150042Phase 12 sites📍 Boston📍 New York General Oncology, Inc. · Tests: Melphalan, BCNU, Vitamin B12B, Vitamin C, Autologous Hematopoietic Stem Cells
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy